Gordon Carl L reported conversion involving 1,703,314 derivative units of Electra Therapeutics, Inc. at $0.00 for $0 on Sep 21, 2026

Conversion
Form 4 code C. Conversion of a derivative security.
Director
DIR
Filed Sep 23, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
1,703,314Series C Convertible Preferred Stock
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
0Indirect · See footnotes
Trade date
Sep 21, 2026Conversion
Filed
Sep 23, 2026, 5:35 PM ET2-day reporting delay
Accession
0000947871-26-000881Code C · Transaction 228555
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 21, 2026Conversion2,002,310$0.00$0Trade 228553
Sep 21, 2026Conversion1,087,934$0.00$0Trade 228554
Sep 21, 2026Buy333,333$15.00$4,999,995Trade 228550
Sep 21, 2026Buy1,000,000$15.00$15,000,000Trade 228552
Sep 21, 2026Conversion758,279$0.00$0Trade 228556
Sep 21, 2026Conversion2,002,310——Trade 228547
Sep 21, 2026Conversion1,087,934——Trade 228548
Sep 21, 2026Conversion1,703,314——Trade 228549
Sep 21, 2026Conversion758,279——Trade 228551
10 transaction rows in this filing. Joint filers share the same rows.

ETRA price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ETRA · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago1d ago
Returns since7d −11%30d −31%90d180d1y

Footnotes in full

F1: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering on September 21, 2026 without payment of further consideration. The Preferred Stock has no expiration date. F2: Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering. F3: These securities are held directly by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VII. F4: These securities are held directly by OrbiMed Genesis Master Fund, L.P. ("OrbiMed Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of OrbiMed Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OrbiMed Genesis. F5: Each of the Reporting Person, OrbiMed Advisors, GP VII and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.